Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mononuclear cell antibody in treating inflammation-related tristimania

A technology for monocytes and depression, applied in the medical field, can solve the problems of ineffectiveness of the crowd, lack of drug treatment strategies, slow onset of effect, etc.

Inactive Publication Date: 2013-05-22
CHINA PHARM UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The new generation of SSRIs has better safety and tolerability, but there are also shortcomings of slow onset of action and ineffectiveness for some people
Clinically, there is still a lack of effective drug treatment strategies for many patients with severe depression, which also puts forward an urgent need for in-depth research on the pathogenesis of depression and the development of new therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mononuclear cell antibody in treating inflammation-related tristimania
  • Application of mononuclear cell antibody in treating inflammation-related tristimania
  • Application of mononuclear cell antibody in treating inflammation-related tristimania

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Example 1. Establishment and behavioral analysis of neuroinflammation-induced mouse depression model

[0011] Experimental materials: C57BL / 6 mice, SPF level, purchased from Experimental Animal Co., Ltd., Academy of Military Medical Sciences.

[0012] experimental method:

[0013] 1. LPS injection into the lateral ventricle: After the mice were anesthetized by intraperitoneal injection of pentobarbital (50 mg / kg), they were carefully and correctly fixed on the mouse stereotaxic instrument. After the head skin is disinfected, carefully expose the skull, locate the bregma as the zero point, and find the skull surface of the lateral ventricle according to the stereotaxic coordinates of the mouse brain (L: 1.0mm, P: 0.5mm, DV: 2.5mm) Location. Animals in the model group were injected with LPS (3 μg / 3 μL normal saline) into the lateral ventricle to induce acute brain inflammation, and the animals in the control group were injected with an equal volume of normal saline into...

Embodiment 2

[0016] Example 2.Ly6c hi Monocyte-specific FITC labeling

[0017] Experimental materials: FITC-microspheres (FITC-dyed (YG), 2.5% [wt / vol]) were purchased from Polyscience, USA, and clodronate liposomes were purchased from FormuMax, USA.

[0018] Experimental method: C57BL / 6 mice were injected with 200 μL clodronate liposomes into the tail vein, and 250 μL FITC-microspheres were injected into the tail vein after 20 hours, and Ly6c was phagocytized by cells hi Monocyte selectable marker. After 24 hours, LPS was injected into the lateral ventricle to induce the depression model.

Embodiment 3

[0019] Example 3.Ly6c hi Central Infiltration Analysis of Monocytes

[0020] Experimental materials: All antibodies related to flow cytometry were purchased from biolegend in the United States, Percoll lymphocyte separation medium was purchased from GE, the flow cytometer was BD FACSCalibur, and the flow cytometry data was analyzed by FlowJo software.

[0021] experimental method:

[0022] 1. Isolation of mononuclear cells in the brain: After the mice were deeply anesthetized, the blood was removed by perfusing about 200 mL of active rapid perfusion with ice PBS (4°C) until the liver turned white and the perfusion was completed. Carefully separate and remove the brain tissue and transfer to a glass homogenizer. Add 6mL of ice-cold PBS to each brain tissue for homogenization. The homogenate is mixed with 100% Percoll solution to make a cell suspension (10mL) containing 30% Percoll, which is carefully added dropwise to 2mL of 70% Percoll solution, and centrifuged at 800g at 18...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines and in particular relates to application of an Ly6c monoclonal antibody in treating tristimania induced by inflammation of the central nervous system. In a model of mouse tristimania induced by the inflammation of the central nervous system, the Ly6chi mononuclear cells in the blood can be soaked to the central nervous system, so that the Ly6chi mononuclear cells are prompted to participate in the inflammation of the central nervous system. The depression behavior can be remarkably worsened by specifically gathering the Ly6chi mononuclear cells. Meanwhile, the depression behavior can be remarkably improved by utilizing the Ly6c antibody to specifically restrain the functions of the Ly6chi mononuclear cells. According to the results, the Ly6chi mononuclear cells have important action in treating the inflammation-related tristimania. Furthermore, the invention discloses the novel application of the Ly6c antibody in treating the inflammation-related tristimania.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of Ly6c monoclonal antibody in the treatment of central inflammation-induced depression. Background technique [0002] Depression is an emotional and psychological disorder syndrome with complex etiology. It has become the fourth leading disease in the world, causing serious social and economic burdens. Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line treatment drugs for clinical depression. The new generation of SSRIs has better safety and tolerability, but also has the disadvantages of slow onset of action and ineffectiveness for some populations. Clinically, there is still a lack of effective drug treatment strategies for many patients with severe depression, which also puts forward an urgent need for in-depth research on the pathogenesis of depression and the development of new therapeutic drugs. [0003] In recent years, the role of immun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P25/24A61P29/00
Inventor 王广基郑啸谢昊郝海平梁艳戴琛谢林
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com